| Studies with proposed classifications to be validated | Validation set | ||
---|---|---|---|---|
Samadder et al. [20] 2013 | Phipps et al. [21] 2015 | Sinicrope et al. [16] 2015 | ||
Study | Iowa Women’s Health Study | Seattle Colon Cancer Family Registry | Phase III randomized trial NCCTG N0147 | DACHS study |
Study design | Cohort | Population-based cohort | Cohort from clinical trial | Population-based cohort |
N | 370 | 1189 | 2720 | 1915 |
Country | US | US | US | Germany |
Population | Women aged 55–69 resident in Iowa | Persons aged 20–74 resident in Washington state and women 50–74 in postmenopausal study | Patients aged 19–86 with resected stage III colon carcinomas in Alabama region | Patients aged 30–96 resident in Rhine-Neckar region |
Cancer | Colorectal | Colorectal | Colon | Colorectal |
Stage | I - IV | I - IV | III | I - IV |
Recruitment time | 1986–2002 | 1998–2007 | 2004–2012 | 2003–2010 |
Treatment | Any | Any | FOLFOX or FOLFOX+cetuximab | Any |
Outcomes | CSS, OS | CSS, OS | DFS | CSS, RFS, OS |
Median follow-up | NR | NR | 4.9 years | 5.3 years |